Results 1 to 10 of about 5,159 (158)

Exploratory observational study with Two-year outcomes of early in-hospital evolocumab in acute coronary syndrome patients undergoing coronary artery bypass grafting [PDF]

Frontiers in Cardiovascular Medicine
AimsPatients with acute coronary syndrome (ACS) who require coronary artery bypass grafting (CABG) remain at very high ischemic risk due to diffuse native disease and vein graft vulnerability.
Giuseppe Nasso, Giuseppe Nasso, Walter Vignaroli, Giuseppe Santarpino, Giuseppe Santarpino, Giuseppe Santarpino, Claudio Larosa, Isabella Rosa, Francesco Bartolomucci, Vincenzo Montemurro, Flavio Fiore, Antongiulio Valenzano, Giacomo Errico, Giacomo Schinco, Mario Siro Brigiani, Gaetano Contegiacomo, Vito Margari, Michele Covelli, Alfredo Marchese, Maria Antonietta De Mola, Ernesto Greco, Giuseppe Speziale, Giuseppe Speziale   +22 more
doaj   +2 more sources

Perfil clínico de los pacientes tratados con evolocumab en unidades hospitalarias de nefrología en España (RETOSS-NEFRO) [PDF]

Nefrología, 2022
Resumen: Antecedentes y objetivo: Describir las características clínicas de los pacientes tratados con evolocumab, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de ...
Marian Goicoechea, Vicente Álvarez, Alfonso Segarra, Manuel Polaina, Guillermo Martín-Reyes, Nicolás Roberto Robles, Verónica Escudero, Cristhian Orellana, Sergio Bea Granell, Joaquín de Juan-Ribera, Milagros Fernández Lucas, Jose Maria Graña, Javier Reque, Rosa Sánchez Hernández, Santiago Villamayor, Jose Luis Górriz   +15 more
doaj   +2 more sources

Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)

Nefrología (English Edition), 2022
Background and objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain.
Marian Goicoechea, Vicente Álvarez, Alfonso Segarra, Manuel Polaina, Guillermo Martín-Reyes, Nicolás Roberto Robles, Verónica Escudero, Cristhian Orellana, Sergio Bea Granell, Joaquín de Juan-Ribera, Milagros Fernández Lucas, Jose Maria Graña, Javier Reque, Rosa Sánchez Hernández, Santiago Villamayor, Jose Luis Górriz   +15 more
doaj   +2 more sources

Evolocumab early reduces IL-1β/IL-17A and improves left ventricular function in STEMI: an observational study in the real world [PDF]

Frontiers in Pharmacology
BackgroundWhile proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively lower low-density lipoprotein cholesterol (LDL-C) levels and reduce the incidence of major adverse cardiovascular events (MACE) in patients with ST-segment ...
Menglong Zhang, Jingyu Liu, Jingxian Wang, Anran Jing, Junfeng Zhang, Changping Li, Zhuang Cui, Yin Liu, Jing Gao, Jing Gao, Jing Gao   +10 more
doaj   +2 more sources

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma [PDF]

Scientific Reports
Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma.
Kirit Singh, Matthew W. Foster, Marlene J. Violette, Anna M. Corcoran, Kelly M. Hotchkiss, Chelsea O. Railton, Emily E. Blandford, Kathryn E. Blethen, Elizabeth L. Thomas, William C. McIntosh, David M. Ashley, Annick Desjardins, Henry S. Friedman, Margaret O. Johnson, Allan Friedman, Stephen Keir, Evan D. Buckley, James E. Herndon, Roger E. McLendon, John H. Sampson, Evan Calabrese, Giselle Y. López, Gerald A. Grant, Anoop P. Patel, Simon G. Gregory, Chuan-Yuan Li, Peter E. Fecci, Mustafa Khasraw   +27 more
doaj   +2 more sources

Clinical effect of proprotein convertase subtilisin/kexin type 9 inhibition in patients undergoing coronary artery bypass surgeryCentral MessagePerspective [PDF]

JTCVS Open
Objectives: To evaluate whether adding evolocumab to statin plus ezetimibe in patients undergoing coronary artery bypass grafting improves lipid control and reduces clinical events.
Giuseppe Nasso, MD, PhD, Alfredo Marchese, PhD, Giuseppe Santarpino, PhD, Walter Vignaroli, MD, Vincenzo Calabrese, MD, Giovanni Taverna, MD, Claudio Larosa, MD, Francesco Bartolomucci, MD, Flavio Fiore, MD, Mario Siro Brigiani, MD, Gaetano Contegiacomo, MD, Ernesto Greco, PhD, Giuseppe Speziale, PhD   +12 more
doaj   +2 more sources

The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis [PDF]

Frontiers in Pharmacology
ObjectiveIn December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022.
Wan Tang, Wan Tang, Wei Li, Wei Li, Anqi Zhang, Huanhuan Wu, Huanhuan Wu, Wei Lu, Wei Lu, Yan Fan, Yan Fan   +10 more
doaj   +2 more sources

Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study [PDF]

Cardiology and Therapy
Introduction The efficacy and safety of evolocumab have been established in clinical trials. This post-marketing surveillance (PMS) study investigated the real-world safety and effectiveness of evolocumab in patients with atherosclerotic cardiovascular ...
Donggyu Moon, Seung-Ho Hur, Sang-Rok Lee, Myung Ho Jeong, Kyung Hoon Cho, Osung Kwon, JinSeon Jeong, Ki Dong Yoo, Evolocumab Post-Marketing Surveillance Research Group   +8 more
doaj   +2 more sources

Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.

PLoS ONE, 2023
ObjectivesDyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice ...
Khalid Al Faraidy, Mousa Akbar, Mohamed Shehri, Mohammad Aljarallah, Gamal Abdin Hussein, Raja Dashti, Ahmad Al Qudaimi, Fahad Al Nouri, Zuhier Awan, Ahmed Essam, Alaa Emara   +10 more
doaj   +1 more source

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

Cardiology and Therapy, 2023
Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia.
Hong Tan, Weimin Li, Zhouqing Huang, Yajun Han, Xuecheng Huang, Dongye Li, Xiaochun Xing, Maria Laura Monsalvo, You Wu, Jackie Mao, Lily Xin, Jiyan Chen, HUA TUO study investigators   +12 more
doaj   +1 more source